
Author Index to Volume 13

- Abeyta Jr., C., 285
Ackerman, V.P., 79
Aldridge, K.E., 311
Al-Sedairy, S., 277
Anderson, L., 149
Ando, T., 235
Anhalt, J.P., 307
Arthur, J., 273
Auriault, C., 423
- Bañón, R., 329
Barnes, W.G., 17
Barrett, M.S., 371
Barriere, S.L., 93
Barry, A.L., 357
Bartlett, M.S., 1
Bergan, T., 103, 127, 191
Biek, R., 25
Bodhidatta, L., 273
Boese-Landgraf, J., 181
Boyken, L.D., 461
Bryant, L., 265
Buonpane, E.A., 99
- Cabezudo, I., 481
Calandra, T., 377
Campos, J.M., 341
Capron, A., 423
Carazo, C., 329
Casal, J., 63
Chae, G.-T., 405
Chan, K.H., 453
Cherubin, C., 25
Childs, S.J., 161
Chin, N.-X., 67, 473, 509
Chmel, H., 149
Chung, L.-P., 439
Chusid, M.J., 367
Cisterna, R., 297
Clark, N.C., 467
Cooksey, R.C., 467
Craven, P.C., 165
Croco, J.L., 371
Csiba, A., 135
Cutler, S.J., 271
- Daly, J.A., 341
D'Amato, R.F., 51
Damonville, M., 423
Davidson, M., 261
Davis, J.R., 289
Davis, R.L., 143
Debs, R., 397
- de la Rosa, M., 269, 329
Dempsey, C.L., 187
Diamond, R.D., 517
Djeu, J.Y., 383
Dobkin, E.D., 99
Doern, G.V., 349
Dolter, J., 265
Donlon, K., 491
Dörner, A., 177
Dunn, W.M., 367
Durazo, F., 71
Dworkin, B.M., 449
- Eberle, H.I., 491
Echevarria, P., 273
Edwards, L.C., 25
Eliopoulos, G.M., 345
Emmanuel, G., 149
Erwin, M.E., 371
- Faro, S., 363
Fedorko, D.P., 41
Fenoll, A., 63
Fernandes, C.J., 79
Fliegelman, R.M., 187
Forward, K.R., 205, 281
Frankel, H., 51
Frenkel, J.K., 1
Fromtling, R.A., 37
Frost, R.W., 93
Fuchs, H.J., 397
Fuchs, P.C., 499
- Gavan, T.L., 499
Gerlach, E.H., 499
Gibert, C.L., 173
Ginnow Johnston, S.L., 241
Glauser, M.P., 377
Glick, E.J., 333
Gobert, R., 227
Goecke, N., 115
Gonzalez, M.A., 71
Goodman, L.J., 333
Gordin, F., 173
Gordon, S., 439
Görtz, G., 181
Gottschall, R.L., 3
Graber, H., 135
Granato, P.A., 217
Grayson, M.L., 345
Green, P.H.R., 473
- Haldane, D.J.M., 337
Hall, R.T., 17
- Hall, S.L., 17
Harris, A.A., 25
Herwaldt, L.A., 461
Higgins, C.S., 297
Hill, B.C., 467
Himes, S.L., 341
Hindler, J.A., 93
Hoban, D.J., 281
Hochstein, L., 51
Hoffman, S., 209
Holcomb, L., 521
Hollis, R., 481
Hopfenmüller, W., 181
Hoshina, S., 473
Huston, B.J., 481, 521
- Ilstrup, D.M., 41
Inderlied, C., 341
Ireland, J., 149
Isobe, R., 235
- Janda, J.M., 265
Jarosinski, P.F., 37
Jessamine, P.G., 281
Jiang, W., 473
Joe, L., 173
Jones, R.N., 77, 253, 317, 353, 371, 499, 521
Jones, T.C., 391
- Kahn, S.M., 473
Kalmár, P., 115
Kambe, J.C., 99
Kaufmann, S.H.E., 429
Kaysner, C.A., 285
Keshav, S., 439
Kim, Y.K., 307
Klemes, A.B., 261
Klimm, K., 345
Knapp, C.C., 45
Koerner, T., 31
Koontz, F.P., 521
Koster, F.T., 157
Kotwas, J., 181
Kraas, E., 115, 177
Krahenbuhl, J.L., 405
- LaGrange, P., 375
LaRocco, M., 341
Lau, N.W.H., 453
LeBar, W.D., 303
Leiva, J., 269
Lie, T., 149

- cefoperazone against, 51
 cefotetan against, 311
 cefoxitin against, 52, 58, 311
 cefpirome against, 371
 cefpirome/tazobactam against, 371
 ceftizoxime against, 311
 chloramphenicol against, 52, 58
 ciprofloxacin against, 347
 clindamycin against, 52, 58
 imipenem against, 58, 347
 meropenem against, 58
 metronidazole against, 52, 58
 penicillin against, 52, 311
 piperacillin against, 58
 sparfloxacin against, 345
 sulbactam against, 51
- Bacteroides melaninogenicus*
 ampicillin/sulbactam against, 353
- Bacteroides ovatus*
 ampicillin/sulbactam against, 353
 cefoperazone against, 52
 cefoperazone/sulbactam against, 52
 cefoxitin against, 52
 cefpirome against, 371
 cefpirome/tazobactam against, 371
 chloramphenicol against, 52
 clindamycin against, 52
 metronidazole against, 52
 penicillin against, 52
 sulbactam against, 52
- Bacteroides* spp.
 cefoxitin against, 58
 chloramphenicol against, 58
 ciprofloxacin against, 183
 clindamycin against, 58
 detection of, 3
 HRE 664 against, 509
 imipenem against, 58
 meropenem against, 58
 metronidazole against, 58
 piperacillin against, 58
- Bacteroides thetaiotamicron*
 ampicillin/sulbactam against, 353
 cefoperazone against, 52
 cefoperazone/sulbactam against, 52
 cefoxitin against, 52
 cefpirome against, 371
 cefpirome/tazobactam against, 371
 chloramphenicol against, 52
 clindamycin against, 52
 metronidazole against, 52
 penicillin against, 52
 sulbactam against, 52
- Bacteroides uniformis*
 ampicillin/sulbactam against, 353
- Bacteroides vulgatus*
 ampicillin/sulbactam against, 353
 cefoperazone against, 52
- cefoperazone/sulbactam against, 52
 cefoxitin against, 52
 cefpirome against, 371
 cefpirome/tazobactam against, 371
 chloramphenicol against, 52
 clindamycin against, 52
 metronidazole against, 52
 penicillin against, 52
 sulbactam against, 52
- Bac-T-Screen
 bacteriuria detected via, 289
- BAY v 3522
 antimicrobial activity of, 349
- Bifidobacterium* spp.
 cefoxitin against, 59
 chloramphenicol against, 59
 clindamycin against, 59
 imipenem against, 59
 meropenem against, 59
 metronidazole against, 59
 piperacillin against, 59
- Bone
Candida albicans infection of, 297
- Borrelia burgdorferi*
 in Lyme disease, 271
- Brain
 fungal infections involving, antifungal agents against, 39
- Branhamella catarrhalis*
 amoxicillin/clavulanic acid against, 349
 BAY v 3522 against, 349
 cefaclor against, 145, 349
 cefixime against, 349
 cefoperazone against, 46
 cefoperazone/sulbactam against, 46
 cefuroxime against, 349
 ciprofloxacin against, 145, 151, 174, 188
 quinolones against, 195
 rapid identification of, 205
 resistance levels of routine isolates of, 89
- Bronchial washings
 measurement of tuberculostearic acid in, 235
- Bronchitis
 ampicillin against, 149
 cefaclor against, 143
 ciprofloxacin against, 143, 149
 cotrimoxazole against, 149
 tetracycline against, 149
- Broth-disk elution test
 ampicillin/sulbactam effectiveness assessed via, 353
- Broth microdilution test
 methicillin resistance in staphylococci assessed via, 9
- Brucella melitensis*
 ciprofloxacin against, 277
- gentamicin against, 277
 lomefloxacin against, 277
 norfloxacin against, 278
 rifampin against, 277
 tetracycline against, 277
 trimethoprim/sulfamethoxazole against, 277
- Brucellosis
 acute, C-reactive protein as prognostic indicator in, 269
- Butoconazole
 effects of on sterol and carbohydrate composition of *Candida albicans*, 31
- Calcofluor white stain
Pneumocystis carinii detected via, 307
 superficial fungal infection detected via, 337
- Campylobacter coli*
 ciprofloxacin against, 334
 erythromycin against, 334
 lomefloxacin against, 334
 norfloxacin against, 334
 temafloxacin against, 334
 tosusfloxacin against, 333
- Campylobacter jejuni*
 ciprofloxacin against, 174, 334, 347
 ciprofloxacin against, 334, 347
 erythromycin against, 334
 imipenem against, 347
 lomefloxacin against, 334
 norfloxacin against, 334
 sparfloxacin against, 347
 temafloxacin against, 334
 tosusfloxacin against, 333
- Campylobacter pylori*
 ciprofloxacin against, 347
 imipenem against, 347
 sparfloxacin against, 347
- Campylobacter* spp.
 quinolones against, 196
 rapid identification of, 273
- Campylobacter upsaliensis*
 sepsis, in acquired hypogammaglobulinemia, 367
- Candida albicans*
 colony-stimulating factors against, 383
 detection of, 291
 osteomyelitis, 297, 517
 in qualitative catheter culture, 224
 sterol and carbohydrate composition of,azole
 antifungal agent effects on, 31
 tumor necrosis factor against, 383
 typing of, 481
- Candidiasis
 disseminated, antifungal agents against, 39

- hepatosplenic, amphotericin B against, 39
pharyngeal, clotrimazole against, 39
vaginal, terconazole against, 31
- Carbenicillin
resistance to, 29
- Carbohydrate
composition, of *Candida albicans*, 31
- Cardiac valves
native, pharmacokinetic behavior of ciprofloxacin in, 115
- Catheter sepsis
heteroresistance of coagulase-negative staphylococci causing, 9
- Catheter tip cultures
qualitative intravascular, bacteremia not predicted via, 223
- Cedecea lapagei*
Ro 24-6778 against, 258
- Cefaclor
adverse effects of, 146
antimicrobial activity of, 143, 349
- Cefamandole
antimicrobial activity of, 80, 321
- Cefazolin
antimicrobial activity of, 67, 320
- Cefixime
antimicrobial activity of, 349
- Cefoperazone
antimicrobial activity of, 45, 51
- Cefoperazone/sulbactam
antimicrobial activity of, 45, 51
- Cefotaxime
antimicrobial activity of, 65, 80, 86, 317, 367, 499, 509
resistance to, 86
as Ro 24-6778 component, 253
structure of, 254
- Cefotetan
antimicrobial activity of, 311
- Cefoxitin
antimicrobial activity of, 52, 58, 80, 311, 499
- Cefpirome
antimicrobial activity of, 371
- Cefpirome/tazobactam
antimicrobial activity of, 371
- Ceftazidime
antimicrobial activity of, 80, 157, 161, 165, 320, 499, 509
resistance to, 86
- Ceftizoxime
antimicrobial activity of, 311
- Ceftriaxone
antimicrobial activity of, 90, 341, 349
resistance to, 90
- Cefuroxime
antimicrobial activity of, 67, 499
- Cell cultures
conventional, herpes simplex virus detected via, 241
- Cephalosporins
antimicrobial activity of, 67, 349
resistance to, 79
- Cephalothin
antimicrobial activity of, 80
resistance to, 87
- Cephadrine
antimicrobial activity of, 320
- Cesarean section
wound infection after, 363
- Chemstrip LN test strip
bacteriuria detected via, 289
- Chitin
composition, of *Candida albicans*, 31
- Chlamydia* spp.
sparfloxacin against, 345
- Chloramphenicol
antimicrobial activity of, 29, 51, 58, 65, 80, 341
resistance to, 87, 341
- CI-978, *See* Sparfloxacin
- Cilofungin
against fungal pathogens, 39
- Cimetidine
ciprofloxacin inhibitory effect on, 135
- Ciprofloxacin
absorption, in enteral nutrition, 99
antimicrobial activity of, 67, 79, 93, 143, 149, 153, 157, 161, 165, 169, 173, 177, 181, 187, 277, 334, 345
extravascular penetration of, 103
inhibitory effect of, 135
partition coefficient of, 104
pharmacokinetic behavior of, 115
resistance to, 79
safety of, after multiple dosing, 191
side effects of, 146, 153
transintestinal elimination of, 127
- Citrobacter amalonaticus*
detection of, 292
- Citrobacter diversus*
amikacin against, 81
ampicillin against, 81
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 81, 256
cephalothen against, 81, 174
ciprofloxacin against, 81
desacetylcefotaxime against, 256
desmethylfloxacin against, 256
desmethylfloxacin/desacetylcefotaxime against, 256
enoxacin against, 81
floxacin against, 256
gentamicin against, 81
HRE 664 against, 509
nalidixic acid against, 81
norfloxacin against, 81
ofloxacin against, 81
Ro 24-6778 against, 256
- Citrobacter freundii*
amikacin against, 72, 81
ampicillin against, 72, 81
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 81, 256
cephalothen against, 81
ciprofloxacin against, 81, 347
desacetylcefotaxime against, 256
desmethylfloxacin against, 256
desmethylfloxacin/desacetylcefotaxime against, 256
enoxacin against, 72, 81
floxacin against, 256
gentamicin against, 81
HRE 664 against, 509
imipenem against, 347
lomefloxacin against, 72
nalidixic acid against, 81
norfloxacin against, 81
ofloxacin against, 81
Ro 24-6778 against, 256
sparfloxacin against, 347
tetracycline against, 72
- Citrobacter* spp.
ceftazidime against, 158, 162
ciprofloxacin against, 158, 162
detection of, 292
- Clindamycin
antifungal activity of, 1
antimicrobial activity of, 52, 58, 80, 165
resistance to, 9
- Clostridium bifermentans*
cefoperazone against, 53
cefoperazone/sulbactam against, 53
cefoxitin against, 53
chloramphenicol against, 53
clindamycin against, 53
metronidazole against, 53
penicillin against, 53
sulbactam against, 53
- Clostridium perfringens*
cefoperazone against, 52
cefoperazone/sulbactam against, 52
cefoxitin against, 52, 58
chloramphenicol against, 52, 58
clindamycin against, 52, 58
imipenem against, 58
meropenem against, 58
metronidazole against, 52, 58
penicillin against, 52
piperacillin against, 58
sulbactam against, 52

- Clostridium* spp.
 ampicillin/sulbactam against, 353
 cefoperazone against, 53
 cefoperazone/sulbactam against, 53
 cefoxitin against, 53, 58
 chloramphenicol against, 53, 58
 clindamycin against, 53, 58
 HRE 664 against, 509
 imipemem against, 57
 meropenem against, 58
 metronidazole against, 53, 58
 penicillin against, 53
 piperacillin against, 58
 sulbactam against, 53
- Clotrimazole
 effects of on sterol and carbohydrate composition of *Candida albicans*, 31
 patterns of usage of, 38
- CMV, *See* Cytomegalovirus
- Colistin
 antimicrobial activity of, 90
 resistance to, 90
- Colony-stimulating factors (CSFs) against *Candida albicans*, 383
 in parasitic diseases, 387
- Colorectal surgery
 ciprofloxacin during, 181
 ciprofloxacin prior to, 177
 metronidazole prior to, 181
 moxalactam during, 181
- Conjugative plasmids
 staphylococcal, relationship of to *Staphylococcus epidermidis* gentamicin-resistance nonconjugative plasmids, 227
- Conjunctivitis
Streptococcus pneumoniae in, 63
- Corynebacterium* spp.
 ciprofloxacin against, 174
- Cotrimoxazole
 antimicrobial activity of, 87, 149
 resistance to, 87
- C-reactive protein
 measurement of in acute brucellosis, 269
- Cryptosporidium* spp.
 rapid identification of, 273
- CSFs, *See* Colony-stimulating factors
- Cystic fibrosis
Pseudomonas infection in, ciprofloxacin against, 153
- Cytochrome P-450
 enzyme system, quinolone inhibition of, 135
- Cytokines
 antimicrobial activity of, 429
 against *Candida albicans*, 383
 in experimental leprosy, 405
- in infection, 375
 in inflammation, 439
 against leukopenia, 391
 in macrophage activation, 411
 in malaria, 435
 in parasitic diseases, 387, 423
 platelet regulation by, 423
 in sepsis syndrome, 397
 in septic shock, 377
- Cytomegalovirus (CMV)
 AD-169 strain, shell vial cell culture technique in detection of, 41
 antibody, detection of, 303
- Daptomycin
 antimicrobial activity of, 67, 245
- 9-Deazainosine
 antifungal activity of, 1
- 14 α -Demethylase
 inhibition, by azole antifungal agents, 31
- Dermatomycoses terconazole against, 31
- Dermatophyte
 infection, detection of, 337
- Desacetylcefotaxime
 as Ro 24-6778 component, 253
 structure of, 254
- Desethylene ciprofloxacin
 extravascular penetration of, 110
 transintestinal elimination of, 128
- Desmethylfleroxacin
 as Ro 24-6778 component, 253
 structure of, 254
- Dexamethasone
 shell vial cell cultures treated with, 41
- Dihydropeptidase-1
 renal, carbapenem antibiotic hydrolysis by, 57
- Dimethyl sulfoxide (DMSO)
 shell vial cell cultures treated with, 41
- Direct Gram stain
Helicobacter pylori detected via, 449
- DMSO, *See* Dimethyl sulfoxide
- DNA fingerprinting
 in typing of *Candida albicans*, 481
- Dot immunobinding assay
 cytomegalovirus antibody detected via, 303
- Edwardsiella tarda*
 rapid identification of, 274
- EIA, *See* Enzyme immunoassay
- Eikenella corrodens*
 ciprofloxacin against, 174
- ELISA, *See* Enzyme-linked immunosorbent assay
- Enoxacin
 antimicrobial activity of, 71, 80
- inhibitory effect of, 135
 partition coefficient of, 104
 resistance to, 86
- Entamoeba histolytica*
 rapid identification of, 275
- Enteral nutrition
 ciprofloxacin absorption in, 99
- Enteric infection
 naladixic acid against, 153
 rapid identification of, 273
- Enterobacter aerogenes*
 amikacin against, 82
 ampicillin against, 82
 cefaclor against, 145
 cefoperazone against, 46
 cefoperazone/sulbactam against, 46
 cefotaxime against, 82, 256
 ceftazidime against, 162
 cephalothin against, 82
 ciprofloxacin against, 81, 145, 162, 347
 desacetylcefotaxime against, 256
 desmethylfleroxacin against, 256
 desmethylfleroxacin/desacetylcefotaxime against, 256
 enoxacin against, 81
 fleroxacin against, 256
 gentamicin against, 82
 imipenem against, 347
 lomefloxacin against, 74
 nalidixic acid against, 81
 norfloxacin against, 81
 ofloxacin against, 81
 Ro 24-6778 against, 256
 sparfloxacin against, 347
- Enterobacter agglomerans*
 amikacin against, 72
 ampicillin against, 72
 enoxacin against, 72
 lomefloxacin against, 72
 Ro 24-6778 against, 258
 tetracycline against, 72
- Enterobacter cloacae*
 amikacin against, 82
 ampicillin against, 82
 cefoperazone against, 46
 cefoperazone/sulbactam against, 46
 cefotaxime against, 82, 256
 ceftazidime against, 162
 cephalothin against, 82
 ciprofloxacin against, 82, 162, 174, 347
 desacetylcefotaxime against, 256
 desmethylfleroxacin against, 256
 desmethylfleroxacin/desacetylcefotaxime against, 256
 detection of, 291
 enoxacin against, 82
 fleroxacin against, 256
 gentamicin against, 82

- imipenem against, 347
 - lomefloxacin against, 74
 - nalidixic acid against, 82
 - norfloxacin against, 82
 - ofloxacin against, 82
 - Ro 24-6778 against, 256
 - sparfloxacin against, 347
- Enterobacteriaceae*
 - cefoperazone/sulbactam against, 45
 - cefoxatime against, 317
 - ciprofloxacin against, 79, 165, 181
 - detection of, 3
 - meropenem against, 57
 - quinolones against, 157, 195
 - resistance to, 85
 - Ro 24-6778 against, 253
 - sparfloxacin against, 345
- Enterobacter sakazakii*
 - epidemiologic typing of, 467
 - Ro 24-6778 against, 258
- Enterobacter* spp.
 - amikacin against, 72
 - ampicillin against, 72
 - ceftazidime against, 158
 - ciprofloxacin against, 143, 158
 - detection of, 292
 - enoxacin against, 72
 - lomefloxacin against, 72
 - in qualitative catheter culture, 224
 - tetracycline against, 72
- Enterococci*
 - cefoperazone against, 46
 - cefoperazone/sulbactam against, 46
 - ceftazidime against, 162
 - ciprofloxacin against, 158, 162, 183
 - detection of, 291
 - moxalactam against, 183
- Enterococcus avium*
 - ciprofloxacin against, 346
 - sparfloxacin against, 346
 - vancomycin against, 346
- Enterococcus durans*
 - Ro 24-6778 against, 253
- Enterococcus faecalis*
 - cefotaxime against, 255
 - ciprofloxacin against, 346
 - daptomycin against, 245
 - desacetylcefotaxime against, 255
 - desmethylfleroxacin against, 255
 - desmethylfleroxacin/desacetylcefotaxime against, 255
 - fleroxacin against, 255
 - Ro 24-6778 against, 255
 - sparfloxacin against, 346
 - vancomycin against, 245, 346
- Enterococcus faecium*
 - ciprofloxacin against, 346
 - Ro 24-6778 against, 258
- sparfloxacin against, 346
- vancomycin against, 346
- Enterococcus hirae*
 - Ro 24-6778 against, 258
- Enzyme immunoassay (EIA)
 - cytomegalovirus antibody detected via, 303
- Enzyme-linked immunosorbent assay (ELISA)
 - herpes simplex virus detected via, 241
 - Lyme disease detected via, 271
- Ergosterol
 - composition, of *Candida albicans*, 31
- Erythromycin
 - antimicrobial activity of, 65, 67, 80, 354
 - resistance to, 9, 29, 87
- Escherichia coli*
 - amikacin against, 72, 82
 - ampicillin against, 72, 82
 - azlocillin against, 93
 - cefoperazone against, 46
 - cefoperazone/sulbactam against, 46
 - cefotaxime against, 82, 256
 - ceftazidime against, 158, 162, 166
 - cephalothin against, 82
 - ciprofloxacin against, 82, 93, 158, 162, 166, 174, 183, 347
 - ciprofloxacin/azlocillin against, 93
 - desacetylcefotaxime against, 256
 - desmethylfleroxacin against, 256
 - desmethylfleroxacin/desacetylcefotaxime against, 256
 - detection of, 292
 - enoxacin against, 72, 82
 - fleroxacin against, 256
 - gentamicin against, 82
 - HRE 664 against, 509
 - imipenem against, 347
 - lomefloxacin against, 72, 74
 - nalidixic acid against, 82
 - norfloxacin against, 82
 - ofloxacin against, 82
 - rapid identification of, 273
 - resistance to, 85
 - Ro 24-6778 against, 256
 - sparfloxacin against, 347
 - tetracycline against, 72
- Eubacterium lentum*
 - ampicillin/sulbactam against, 353
- Eubacterium* spp.
 - cefoperazone against, 53
 - cefoperazone/sulbactam against, 53
 - cefoxitin against, 53, 59
 - chloramphenicol against, 53, 59
 - clindamycin against, 53, 59
 - imipenem against, 59
 - meropenem against, 59
 - metronidazole against, 53, 59
- penicillin against, 53
- piperacillin against, 59
- sulbactam against, 53
- Eye
 - fungal infections involving, antifungal agents against, 39
- Feces
 - ciprofloxacin elimination via, 128, 177
- FiltraCheck-UTI
 - disposable colorimetric screen, bacteriuria
 - detected via, 289
- Flavobacterium* spp.
 - Ro 24-6778 against, 253
- Fleroxacin
 - as Ro 24-6778 component, 253
- Fluconazole
 - antimicrobial activity of, 517
 - against fungal pathogens, 39
- Flucytosine
 - patterns of usage of, 37
- 5-Fluorocystine
 - antifungal activity of, 1
- Formylciprofloxacin
 - transintestinal elimination of, 128
- Fucidin
 - antimicrobial activity of, 87
 - resistance to, 87
- Fungus
 - reclassification of *Pneumocystis* as, 1
 - superficial infection by, laboratory diagnosis of, 337
- Fusarium moniliforme*
 - proteolytic enzymes of, 491
- Fusidic acid
 - antimicrobial activity of, 80
- Fusobacterium* spp.
 - cefoperazone against, 53
 - cefoperazone/sulbactam against, 53
 - cefoxitin against, 53, 58
 - chloramphenicol against, 53, 58
 - clindamycin against, 53, 58
 - imipenem against, 58
 - meropenem against, 58
 - metronidazole against, 53, 58
 - penicillin against, 53
 - piperacillin against, 58
 - sulbactam against, 53
- Gastrointestinal tract
 - ciprofloxacin absorption from, 99
- Gen-Probe PACE system
 - Neisseria gonorrhoeae* in urogenital samples detected via, 217
- Gentamicin
 - antimicrobial activity of, 29, 80, 277
 - resistance to, 9, 85, 227

- Giardia lamblia*
rapid identification of, 275
- Giardia* spp.
rapid identification of, 273
- Giemsa stain
Pneumocystis carinii detected via, 307
- Glucan
composition, of *Candida albicans*, 31
- Glutaraldehyde
pharmacokinetic behavior of ciprofloxacin in
valves treated with, 115
- GM-CSF, *See* Granulocyte-macrophage colony-stimulating factor
- Gram-Weigert stain
Pneumocystis carinii detected via, 307
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)
against leukopenia, 391
in parasitic diseases, 387
- Granulocytopenia
fungal infections with, 39
in infection, 391
- Haemophilus ducreyi*
quinolones against, 195
- Haemophilus influenzae*
amoxicillin/clavulanic acid against, 349
ampicillin/sulbactam against, 341
BAY v 3522 against, 349
cefaclor against, 145, 349
cefexime against, 349
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefuroxime against, 349
ciprofloxacin against, 143, 188
quinolones against, 195
- Haemophilus parainfluenzae*
ampicillin against, 151
cefaclor against, 145
ciprofloxacin against, 145, 150
- Haemophilus* spp.
cefotaxime against, 317
ciprofloxacin against, 149, 174
meropenem against, 57
- Hafnia alvei*
amikacin against, 72
ampicillin against, 72
enoxacin against, 72
lomefloxacin against, 72
Ro 24-6778 against, 258
tetracycline against, 72
- Helicobacter pylori*
detection of, 449
ribosomal 16S gene segments, direct detection
and amplification of, 473
- Herpes simplex virus (HSV)
rapid detection of, 241
- HIV, *See* Human immunodeficiency virus
- HRE 664
antimicrobial activity of, 509
- HSV, *See* Herpes simplex virus
- Human immunodeficiency virus (HIV)
fungal infections with, 37
- Hypogammaglobulinemia
acquired, *Campylobacter upsaliensis* sepsis in, 367
- IFA, *See* Indirect immunofluorescence assay
- Imidazoles
effects of on sterol and carbohydrate composition
of *Candida albicans*, 31
- Imipenem
antimicrobial activity of, 57, 86, 345, 509
resistance to, 86
- Immunoblotting
cytomegalovirus antibody detected via, 303
- Immunocompromised patients
fungal infections in, 37
- Indirect hemagglutination
cytomegalovirus antibody detected via, 303
- Indirect immunofluorescence assay (IFA)
cytomegalovirus antibody detected via, 303
- Lyme disease detected via, 271
- Infants
Enterobacter sazkii infection in, 467
premature, nasopharyngeal cultures of, coagulase-negative staphylococcal isolates from, 17
- Inflammation
macrophages in, 439
- Interferon-
antimicrobial activity of, 411, 429
in experimental leprosy, 405
in malaria, 435
in parasitic diseases, 387
- Interleukins
antimicrobial activity of, 429
in malaria, 435
- Intravenous therapy
standard, ciprofloxacin after, 187
- Itraconazole
against fungal pathogens, 39
- JK group diphtheroids
ciprofloxacin against, 346
sparfloxacin against, 346
vancomycin against, 346
- Kanamycin
antimicrobial activity of, 29
- Keratitis
fungal, proteases in pathogenesis of, 491
- Ketoconazole
antifungal activity of, 1
patterns of usage of, 37
- Kidneys
ciprofloxacin elimination via, 127
fungal infections involving, antifungal agents against, 39
transplantation of, *Mycoplasma hominis* infection after, 329
- Klebsiella oxytoca*
amikacin against, 72
ampicillin against, 72
cefoperazone against, 46
cefoperazone/sulbactam against, 46
ceftazidime against, 162
ciprofloxacin against, 162
enoxacin against, 72
lomefloxacin against, 72
rapid identification of, 274
tetracycline against, 72
- Klebsiella ozaenae*
amikacin against, 73
ampicillin against, 73
enoxacin against, 73
lomefloxacin against, 73
tetracycline against, 73
- Klebsiella pneumoniae*
amikacin against, 73, 82
ampicillin against, 73, 82
azlocillin against, 93
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 82
ceftazidime against, 162
cephalothin against, 82
ciprofloxacin against, 82, 93, 162, 188, 347
ciprofloxacin/azlocillin against, 93
detection of, 291
enoxacin against, 73, 82
gentamicin against, 82
imipenem against, 347
lomefloxacin against, 73
nalidixic acid against, 82
norfloxacin against, 82
ofloxacin against, 82
sparfloxacin against, 347
tetracycline against, 73
- Klebsiella* spp.
amikacin against, 73
ampicillin against, 73
cefotaxime against, 256

- ceftazidime against, 158
 ciprofloxacin against, 143, 149, 151, 158, 174, 183
 desacetylcefotaxime against, 256
 desmethylfleroxacin against, 256
 desmethylfleroxacin/desacetylcefotaxime against, 256
 enoxacin against, 73
 fleroxacin against, 256
 HRE 664 against, 509
 lomefloxacin against, 73
 Ro 24-6778 against, 256
 tetracycline against, 73
- β -Lactam susceptibility of coagulase-negative staphylococci to, 9
- β -Lactamase
 in *Staphylococcus epidermidis*, 69
 sulbactam inhibition of, 45, 51
- Lactobacillus* spp.
 ceftoxitin against, 59
 chloramphenicol against, 59
 clindamycin against, 59
 imipenem against, 59
 meropenem against, 57, 59
 metronidazole against, 59
 piperacillin against, 59
- Lanosterol
 composition, of *Candida albicans*, 31
- Latamoxef, *See* Moxalactam
- Latex agglutination test
 bacterial enteric infection assessed via, 273
 cytomegalovirus antibody detected via, 303
- Legionella pneumophila*
 ciprofloxacin against, 144
 interleukins against, 429
 quinolones against, 195
- Leishmania* spp.
 infection, colony-stimulating factors against, 387
- Leprosy
 experimental, interferon- γ in, 405
- Leukopenia
 GM-CSF against, 391
- Listeria monocytogenes*
 ciprofloxacin against, 346
 interleukins against, 429
 sparfloxacin against, 346
 vancomycin against, 346
- Lomefloxacin (SC-47111, NY-198)
 antimicrobial activity of, 71, 277, 334
- Lungs
 injury of, in TNF α induced sepsis syndrome, 397
- Lyme disease
 tests for, evaluation of, 271
- Lysis centrifugation system
 fungemia detected via, 39
- Macrophages
 activation of, in antimicrobial host defense, 411
 in inflammation, 439
- Malaria
 tumor necrosis factor in, 435
- Malassezia furfur*
 detection of, 337
- Mannan
 composition, of *Candida albicans*, 31
- MBCs, *See* Minimum bactericidal concentrations
- Meningitis
Enterobacter sazkii in, 467
 group G streptococcal, in AIDS, 261
Streptococcus pneumoniae in, 63
- Meropenem (SM-7338)
 antimicrobial activity of, 57
- Methenamine
 antimicrobial activity of, 320
- Methenamine silver stain
 modified, *Pneumocystis carinii* detected via, 307
- Methicillin
 antimicrobial activity of, 80
 resistance to, 9, 87
- Metronidazole
 antimicrobial activity of, 51, 58, 165, 181, 371
 ciprofloxacin inhibitory effect on, 135
- Mezlocillin
 antimicrobial activity of, 320
- Miconazole
 antifungal activity of, 1
 effects of on sterol and carbohydrate composition of *Candida albicans*, 31
- MICs, *See* Minimum inhibitory concentrations
- Milk
Salmonella typhimurium outbreak carried via, 25
- Minimum bactericidal concentrations (MBCs)
 for ceftoxitin, 59
 for chloramphenicol, 59
 for clindamycin, 59
 for imipenem, 59
 for meropenem, 59
 for metronidazole, 58
 for penicillin, 262
 for piperacillin, 59
- Minimum inhibitory concentrations (MICs)
 for amikacin, 72, 80
 for amoxicillin/clavulanic acid, 350, 357
 for ampicillin, 72, 80, 341, 349
 for ampicillin/sulbactam, 343, 353
 for azlocillin, 86, 94
 for BAY v 3522, 349
 for cefaclor, 350
 for cefamandole, 67
 for cefazolin, 67
 for cefixime, 350
 for cefoperazone, 45, 52
 for cefoperazone/sulbactam, 52
 for cefotaxime, 64, 80, 254
 for cefotetan, 311
 for ceftoxitin, 52, 311
 for ceftiofime, 371
 for ceftiofime/tazobactam, 371
 for ceftazidime, 86
 for ceftizoxime, 311
 for ceftriaxone, 343
 for cefuroxime, 67, 343, 350
 for cephalothin, 80
 for chloramphenicol, 52, 64, 343
 for ciprofloxacin, 79, 86, 94, 169, 174, 179, 187, 278, 346
 for clindamycin, 52
 for daptomycin, 248
 for desacetylcefotaxime, 254
 for desmethylfleroxacin, 254
 for enoxacin, 72, 80
 for erythromycin, 64
 for fleroxacin, 254
 for gentamicin, 80, 278
 for HRE 664, 509
 for imipenem, 57, 86, 346
 for lomefloxacin, 72, 278
 for methicillin, 9
 for metronidazole, 52
 for naladixic acid, 80
 for norfloxacin, 80
 for ofloxacin, 80
 for optochin, 63
 for oxacillin, 9
 for penicillin, 52, 64, 262, 311
 for piperacillin, 58, 86
 for rifampin, 278, 343
 for Ro 24-6778, 253
 for sparfloxacin, 345
 for sulbactam, 52
 for tetracycline, 64, 72, 278
 for ticarcillin, 86
 for ticarcillin/clavulanic acid, 357
 for tosufloxacin, 333
 for trimethoprim/sulfamethoxazole, 278
 for vancomycin, 67, 248, 346
- Morganella morganii*
 amikacin against, 73, 83

- ampicillin against, 73, 83
 cefoperazone against, 46
 cefoperazone/sulbactam against, 46
 cefotaxime against, 83, 256
 ceftazidime against, 162
 cephalothin against, 83
 ciprofloxacin against, 83, 162
 desacetylcefotaxime against, 256
 desmethylfloxacin against, 256
 desmethylfloxacin/desacetylcefotaxime against, 256
 enoxacin against, 73, 83
 fleroxacin against, 256
 gentamicin against, 83
 lomefloxacin against, 73
 nalidixic acid against, 83
 norfloxacin against, 83
 ofloxacin against, 83
 Ro 24-6778 against, 256
 tetracycline against, 73
- Morganella* spp.
 HRE 664 against, 509
- Moxalactam
 in colorectal surgery, 181
- MRC-5 shell vials
 cytomegalovirus detected via, 41
 herpes simplex virus detected via, 241
- Mycobacterium avium-intracellulare* complex
 ciprofloxacin against, 347
 imipenem against, 347
 sparfloxacin against, 347
- Mycobacterium bovis*
 interleukins against, 429
- Mycobacterium fortuitum*
 ciprofloxacin against, 174
- Mycobacterium leprae*
 interferon- γ against, 405
 interleukins against, 429
- Mycobacterium* spp.
 sparfloxacin against, 345
- Mycobacterium tuberculosis*
 interleukins against, 429
 tuberculostearic acid isolated from, 235
- Mycoplasma hominis*
 in renal transplant patients, 329
 in wound infections, after Cesarean section, 363
- Mycoplasma pneumoniae*
 ciprofloxacin against, 144
- Mycoplasma* spp.
 sparfloxacin against, 345
- Naegleria* spp.
 transmission of, 1
- Nafcillin
 resistance to, 9
- Nalidixic acid
 antimicrobial activity of, 29, 80, 153, 157
- Nasoduodenal tube
 ciprofloxacin administration via, 99
- Nasogastric tube
 ciprofloxacin administration via, 99
- Nasopharyngeal cultures
 serial, of premature infants, coagulase-negative staphylococcal isolates from, 17
- Neisseria gonorrhoeae*
 cefotaxime against, 499
 cefoxitin against, 499
 ceftazidime against, 499
 cefuroxime against, 499
 quinolones against, 195
 rapid identification of, 265
 in urogenital samples, detection of, 217
- Neisseria meningitidis*
 cefoperazone against, 46
 cefoperazone/sulbactam against, 46
 detection of, 3
 quinolones against, 195
- Neisseria* spp.
 cefoxatime against, 317
 meropenem against, 57
 rapid identification of, 205
- Norfloxacin
 antimicrobial activity of, 80, 278, 334
 partition coefficient of, 104
 resistance to, 86
- Nosocomial infections
 coagulase-negative staphylococci from, biotyping of, 461
Enterobacter sakazakii in, 467
 in premature infants, coagulase-negative staphylococci from, 17
- NY-198, *See* Lomefloxacin
- Ofloxacin
 antimicrobial activity of, 67, 80
 partition coefficient of, 104
 resistance to, 86
- Optochin
Streptococcus pneumoniae resistance to, 63
- Organ transplantation
 fungal infections with, 37
- Osteomyelitis
Candida spp., fluconazole against, 517
Staphylococcus aureus, ciprofloxacin against, 169
- Otitis media
Streptococcus pneumoniae in, 63
- Oxacillin
 antimicrobial activity of, 67
 resistance to, 9
- Oxociprofloxacin
 extravascular penetration of, 110
 transintestinal elimination of, 128
- Oxoid signal system
 bacteremia detected via, 3
- Papanicolaou stain
Pneumocystis carinii detected via, 307
- Parasitic diseases
 colony-stimulating factors in, 387
 platelets in, 423
- Passive hemagglutination kit
 Lyme disease detected via, 271
- Pasteurella multocida*
 ciprofloxacin against, 347
 imipenem against, 347
 sparfloxacin against, 347
- PD-131501, *See* Sparfloxacin
- Pefloxacin
 inhibitory effect of, 135
 partition coefficient of, 104
- Penicillin
 antimicrobial activity of, 52, 65, 80, 311
 resistance to, 9, 87
- Pentamidine
 antifungal activity of, 1
- Peptolide
 antimicrobial activity of, 67
- Peptostreptococcus* spp.
 cefoxitin against, 58
 chloramphenicol against, 58
 clindamycin against, 58
 imipenem against, 58
 meropenem against, 58
 metronidazole against, 58
 piperacillin against, 58
- Phagocyte function
 cytokine role in, against *Candida albicans*, 383
- Pharyngotonsillitis
 group A streptococcal, rapid diagnosis of, 209
- Piperacillin
 antimicrobial activity of, 58, 80, 320
 resistance to, 86
- Pivampicillin
 antimicrobial activity of, 320
- Pivmecillinan
 antimicrobial activity of, 320
- Platelets
 in parasitic diseases, 423
- Plesiomonas shigelloides*
 ciprofloxacin against, 334
 erythromycin against, 334
 lomefloxacin against, 334
 norfloxacin against, 334
 rapid identification of, 274
 temafloxacin against, 334
 tosufloxacin against, 334
- Pleural effusions
 tuberculostearic acid in, measurement of, 235

- Pneumocystis carinii*
detection of, 307
- Pneumocystis* spp.
reclassification of as fungus, 1
- Pneumonia
lobar, *Streptococcus pneumoniae* in, 63
Pneumocystis carinii, detection of, 307
- Polymerase chain reaction
amplification, *Helicobacter pylori* detected
via, 473
- Porcine valves
pharmacokinetic behavior of ciprofloxacin in, 115
- Potassium hydroxide
in diagnosis of superficial fungal infection, 337
- Premature infants
nasopharyngeal cultures of, coagulase-negative staphylococcal isolates from, 17
- Primaquine
antifungal activity of, 1
- Proteus mirabilis*
amikacin against, 73
ampicillin against, 73, 83
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 83, 256
ceftazidime against, 162, 166
cephalothin against, 83
ciprofloxacin against, 83, 162, 166, 174, 188, 347
desacetylcefotaxime against, 256
desmethylfleroxacin against, 256
desmethylfleroxacin/desacetylcefotaxime against, 256
detection of, 292
enoxacin against, 73, 83
fleroxacin against, 256
gentamicin against, 83
HRE 664 against, 509
imipenem against, 347
lomefloxacin against, 73
nalidixic acid against, 83
norfloxacin against, 83
ofloxacin against, 83
Ro 24-6778 against, 256
sparfloxacin against, 347
tetracycline against, 73
- Proteus rettgeri*
amikacin against, 83
cefotaxime against, 83
cephalothin against, 83
ciprofloxacin against, 83
enoxacin against, 83
gentamicin against, 83
nalidixic acid against, 83
norfloxacin against, 83
ofloxacin against, 83
- Proteus* spp.
ceftazidime against, 158
ciprofloxacin against, 158
detection of, 292
in qualitative catheter culture, 225
- Proteus stuartii*
amikacin against, 84
ampicillin against, 84
cefotaxime against, 84
cephalothin against, 84
ciprofloxacin against, 84
ciprofloxacin resistance in, 85
enoxacin against, 84
gentamicin against, 84
nalidixic acid against, 84
norfloxacin against, 84
ofloxacin against, 84
- Proteus vulgaris*
amikacin against, 84
ampicillin against, 84
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 84, 257
cephalothin against, 84
ciprofloxacin against, 84, 347
desacetylcefotaxime against, 257
desmethylfleroxacin against, 257
desmethylfleroxacin/desacetylcefotaxime against, 257
enoxacin against, 84
fleroxacin against, 257
gentamicin against, 84
imipenem against, 347
lomefloxacin against, 74
nalidixic acid against, 84
norfloxacin against, 84
ofloxacin against, 84
Ro 24-6778 against, 257
sparfloxacin against, 347
- Providencia alcalifaciens*
lomefloxacin against, 74
Ro 24-6778 against, 258
- Providencia rettgeri*
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 257
ceftazidime against, 162
ciprofloxacin against, 162
desacetylcefotaxime against, 257
desmethylfleroxacin against, 257
desmethylfleroxacin/desacetylcefotaxime against, 257
fleroxacin against, 257
lomefloxacin against, 74
Ro 24-6778 against, 257
- Providencia* spp.
ceftazidime against, 158
ciprofloxacin against, 79, 158
HRE 664 against, 509
- Providencia stuartii*
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 257
ciprofloxacin against, 80
desacetylcefotaxime against, 257
desmethylfleroxacin against, 257
desmethylfleroxacin/desacetylcefotaxime against, 257
fleroxacin against, 257
Ro 24-6778 against, 257
- Pseudomonas acidovorans*
Ro 24-6778 against, 258
- Pseudomonas aeruginosa*
amikacin against, 73
ampicillin against, 73
azlocillin against, 86, 93
ceftazidime against, 145
cefoperazone against, 46
cefoperazone/sulbactam against, 46, 47
cefotaxime against, 86, 257
ceftazidime against, 86, 162, 166
ciprofloxacin against, 79, 86, 93, 143, 153, 162, 165, 169, 173, 188, 347
ciprofloxacin/azlocillin against, 93
colistin against, 90
desacetylcefotaxime against, 257
desmethylfleroxacin against, 257
desmethylfleroxacin/desacetylcefotaxime against, 257
detection of, 291
enoxacin against, 73, 86
fleroxacin against, 257
gentamicin against, 86
imipenem against, 86, 347
lomefloxacin against, 73
norfloxacin against, 86
ofloxacin against, 86
piperacillin against, 86
proteolytic enzymes of, 491
in qualitative catheter culture, 225
quinolones against, 157, 195
resistance to, 85
Ro 24-6778 against, 257
sparfloxacin against, 347
tetracycline against, 73
ticarcillin against, 86
- Pseudomonas cepacia*
cefoperazone against, 46
cefoperazone/sulbactam against, 46
ciprofloxacin against, 347
imipenem against, 347
quinolones against, 196
Ro 24-6778 against, 258
sparfloxacin against, 347
- Pseudomonas fluorescens*

- azlocillin against, 86
 ceftazidime against, 86
 ciprofloxacin against, 86
 enoxacin against, 86
 gentamicin against, 86
 imipenem against, 86
 lomefloxacin against, 74
 piperacillin against, 86
 resistance to, 85
 Ro 24-6778 against, 258
 ticarcillin against, 86
Pseudomonas maltophilia
 azlocillin against, 86
 cefoperazone against, 46
 cefoperazone/sulbactam against, 46
 ceftazidime against, 86
 ciprofloxacin against, 86
 enoxacin against, 86
 gentamicin against, 86
 imipenem against, 86
 piperacillin against, 86
 in qualitative catheter culture, 225
 resistance to, 85
 ticarcillin against, 86
Pseudomonas putida
 Ro 24-6778 against, 258
Pseudomonas spp.
 amikacin against, 73
 ampicillin against, 73
 cefoperazone/sulbactam against, 45
 cefoxatime against, 317
 ceftazidime against, 158
 ciprofloxacin against, 149, 151, 158
 enoxacin against, 73
 lomefloxacin against, 73
 meropenem against, 57
 quinolones against, 195
 resistance to, 85
 Ro 24-6778 against, 253
 tetracycline against, 73
Pseudomonas stutzeri
 cefaclor against, 145
 ciprofloxacin against, 145
 Ro 24-6778 against, 258

 Quality assurance
 as hospital epidemiology component, 197
 Quinolones
 absorption of, in enteral nutrition, 99
 antimicrobial activity of, 67, 71, 79, 93, 143, 149, 153, 157, 161, 165, 169, 173, 177, 181, 187, 191, 195, 345
 extravascular penetration of, 103
 metabolic interactions of, 135
 pharmacokinetic behavior of, 115
 resistance patterns to, 79
 serum bactericidal activity of, 93

 transintestinal elimination of, 127
 Resin blood cultures
 positive, in antimicrobial selection, 281
 Rifampicin
 antimicrobial activity of, 80
 resistance to, 87
 Rifampin
 antimicrobial activity of, 277, 341
 RNA dot blot assay
Helicobacter pylori detected via, 473
 RNA homology
 in reclassification of *Pneumocystis*, 1
 Ro 24-6778
 antimicrobial activity of, 253
 structure of, 254
Rotavirus spp.
 rapid identification of, 274

Salmonella agona
 frequency of in salmonellosis occurrence, 25
Salmonella braenderup
 frequency of in salmonellosis occurrence, 25
Salmonella choleraesuis
 frequency of in salmonellosis occurrence, 27
Salmonella derby
 frequency of in salmonellosis occurrence, 25
Salmonella enteritidis
 cefotaxime against, 257
 desacetylcefotaxime against, 257
 desmethylfloxacin against, 257
 desmethylfloxacin/desacetylcefotaxime against, 257
 fleroxacin against, 257
 frequency of in salmonellosis occurrence, 25
 Ro 24-6778 against, 257
Salmonella hadar
 frequency of in salmonellosis occurrence, 25
Salmonella heidelberg
 frequency of in salmonellosis occurrence, 25
Salmonella infantis
 frequency of in salmonellosis occurrence, 29
Salmonella newport
 frequency of in salmonellosis occurrence, 29
Salmonella spp.
 amikacin against, 73
 ampicillin against, 73, 85
 cefotaxime against, 85
 cephalothin against, 85
 ciprofloxacin against, 85, 333
 detection of, 292
 enoxacin against, 73, 85
 erythromycin against, 334
 gentamicin against, 85
 HRE 664 against, 509
 lomefloxacin against, 73, 334
 nalidixic acid against, 85
 norfloxacin against, 85, 334
 ofloxacin against, 85
 rapid identification of, 273
 serogroup E, monoclonal antibodies for, 453
 temafloxacin against, 334
 tetracycline against, 73
 tosufloxacin against, 334
Salmonella thompson
 frequency of in salmonellosis occurrence, 25
Salmonella typhimurium
 frequency of, after milkborne outbreak of, 25
 Salmonellosis
 human, *Salmonella typhimurium* in, 25
 SC-47111, *See* Lomefloxacin
 SCH-39304
 against fungal pathogens, 39
Schistosoma mansoni
 infection, antischistosome properties of platelets in, 423
 Sepsis
 in AIDS, 261
Campylobacter upsaliensis, in acquired hypogammaglobulinemia, 367
 catheter, heteroresistance of coagulase-negative staphylococci causing, 9
 lung injury in, 397
 Septicemia
 detection of, 3
 Septic shock
 cytokines in, 377
Serratia marcescens
 amikacin against, 73, 85
 ampicillin against, 73, 84
 azlocillin against, 93
 cefoperazone against, 46
 cefoperazone/sulbactam against, 46
 cefotaxime against, 85, 257
 ceftazidime against, 162, 166
 cephalothin against, 84
 ciprofloxacin against, 84, 93, 162, 174, 188, 347
 ciprofloxacin/azlocillin against, 93
 desacetylcefotaxime against, 257
 desmethylfloxacin against, 257
 desmethylfloxacin/desacetylcefotaxime against, 257
 enoxacin against, 73, 84

- fleroxacin against, 257
gentamicin against, 85
HRE 664 against, 509
imipenem against, 347
lomefloxacin against, 73
nalidixic acid against, 84
norfloxacin against, 84
ofloxacin against, 84
in qualitative catheter culture, 225
Ro 24-6778 against, 257
sparfloxacin against, 347
tetracycline against, 73
- Serratia* spp.
ceftazidime against, 158
ciprofloxacin against, 79, 158
lomefloxacin against, 74
quinolones against, 196
- Serum bactericidal activity
from azlocillin, 93
from ciprofloxacin, 93
from ciprofloxacin/azlocillin, 93
- Shell vial cell culture technique
cytomegalovirus detected via, 41
herpes simplex virus detected via, 241
- Shigella boydii*
rapid identification of, 274
- Shigella dysenteriae*
lomefloxacin against, 74
rapid identification of, 274
- Shigella flexneri*
rapid identification of, 273
- Shigella sonnei*
ciprofloxacin against, 174
rapid identification of, 273
- Shigella* spp.
ciprofloxacin against, 333
erythromycin against, 334
HRE 664 against, 509
lomefloxacin against, 74, 334
norfloxacin against, 334
rapid identification of, 273
Ro 24-6778 against, 258
temafloxacin against, 334
tosufloxacin against, 334
- Slime production
in coagulase-negative staphylococci, 17, 461
- SM-7338, *See* Meropenem
- Soft tissue infection
ceftazidime against, 165
ciprofloxacin against, 165
clindamycin against, 165
metranidazole against, 165
- Sparfloxacin (AT-4140, CI-978, PD 131501)
antimicrobial activity of, 345
- Sputum
tuberculostearic acid in, measurement of, 235
- Staphylococci
biotyping of, 461
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefoxatime against, 317
cephalosporins against, 67
ciprofloxacin against, 79
detection of, 292
 β -lactam susceptibility of, 9
from nasopharyngeal cultures of premature infants, 17
oxacillin-susceptible meropenem against, 57
in qualitative catheter culture, 225
quinolones against, 157, 195
Ro 24-6778 against, 253
- Staphylococcus aureus*
amikacin against, 74
amoxicillin/clavulanic acid against, 357
ampicillin against, 74
azlocillin against, 93
catheter sepsis caused by, β -lactam susceptibility of, 9
cefaclor against, 145
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 255
ceftazidime against, 162, 166
cephalothin against, 87
chloramphenicol against, 87
ciprofloxacin against, 87, 93, 145, 162, 166, 173, 346
ciprofloxacin/azlocillin against, 93
conjugative plasmids, relationship of to staphylococcal gentamicin-resistance nonconjugative plasmids, 227
cotrimoxazole against, 87
daptomycin against, 245
desacetylcefotaxime against, 255
desmethylfleroxacin against, 255
desmethylfleroxacin/desacetylcefotaxime against, 255
detection of, 3
enoxacin against, 74, 87
erythromycin against, 87
fleroxacin against, 255
fucidin against, 87
gentamicin against, 87
HRE 664 against, 509
lomefloxacin against, 74
methicillin against, 87
norfloxacin against, 87
osteomyelitis, ciprofloxacin against, 169
penicillin against, 87
in qualitative catheter culture, 224
quinolones against, 195
resistance to, 85
rifampicin against, 87
- Ro 24-6778 against, 255
sparfloxacin against, 346
tetracycline against, 74, 87
ticarcillin/clavulanic acid against, 357
vancomycin against, 87, 245, 346
- Staphylococcus epidermidis*
amikacin against, 74
ampicillin against, 74
biotyping of, 461
catheter sepsis caused by, β -lactam susceptibility of, 9
cefotaxime against, 255
cephalosporins against, 67
cephalothin against, 87
cephotaxime against, 87
chloramphenicol against, 87
ciprofloxacin against, 87, 158, 174, 183, 188, 346
cotrimoxazole against, 87
daptomycin against, 67, 245
desacetylcefotaxime against, 255
desmethylfleroxacin against, 255
desmethylfleroxacin/desacetylcefotaxime against, 255
detection of, 3
enoxacin against, 74
enoxacin against, 87
erythromycin against, 87
fleroxacin against, 255
gentamicin-resistance nonconjugative plasmids in, staphylococcal conjugative plasmid relationship to, 227
HRE 664 against, 509
lomefloxacin against, 74
methicillin against, 87
norfloxacin against, 87
penicillin against, 87
resistance to, 85
Ro 24-6778 against, 255
from serial nasopharyngeal cultures of premature infants, 17
sparfloxacin against, 346
tetracycline against, 74, 87
vancomycin against, 245, 346
- Staphylococcus hemolyticus*
cephalosporins against, 67
- Staphylococcus saprophyticus*
cephalothin against, 87
cephotaxime against, 87
chloramphenicol against, 87
ciprofloxacin against, 87
cotrimoxazole against, 87
enoxacin against, 87
erythromycin against, 87
methicillin against, 87
norfloxacin against, 87
penicillin against, 87
quinolones against, 196

- resistance to, 85
tetracycline against, 87
- Sterol
composition, of *Candida albicans*, 31
- Stomatococcus mucilaginosus*
bacteremia, detection of, 521
- Stools
microscopic examination of, bacterial
enteric infections assessed via, 273
- Streptococcal antigen
group A, detection of from throat
swabs, 209
- Streptococci
amikacin against, 74
ampicillin against, 74
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 88
ceftazidime against, 166
cephalothin against, 88
ciprofloxacin against, 79, 88, 166, 174,
346
cotrimoxazole against, 88
detection of, 3
enoxacin against, 74, 88
erythromycin against, 88
HRE 664 against, 509
lomefloxacin against, 74
in meningitis, 261
meropenem against, 57
penicillin against, 88
in qualitative catheter culture, 225
quinolones against, 195
resistance levels of routine isolates of,
89
Ro 24-6778 against, 253
sparfloxacin against, 346
tetracycline against, 74
vancomycin against, 346
- Streptococcus agalactiae*
cefotaxime against, 88, 255
cephalothin against, 88
ciprofloxacin against, 88
cotrimoxazole against, 88
desacetylcefotaxime against, 255
desmethylfleroxacin against, 255
desmethylfleroxacin/desacetylcefotaxime
against, 255
detection of, 292
enoxacin against, 88
erythromycin against, 88
fleroxacin against, 255
penicillin against, 88
resistance levels of routine isolates of,
89
Ro 24-6778 against, 255
- Streptococcus faecalis*
cefotaxime against, 88
- cephalothin against, 88
ciprofloxacin against, 88
cotrimoxazole against, 88
enoxacin against, 88
erythromycin against, 88
penicillin against, 88
resistance levels of routine isolates of,
89
- Streptococcus milleri*
resistance levels of routine isolates of,
89
- Streptococcus mitior*
resistance levels of routine isolates of,
89
- Streptococcus pneumoniae*
amikacin against, 74
ampicillin against, 74
cefaclor against, 145
cefoperazone against, 46
cefoperazone/sulbactam against, 46
cefotaxime against, 88, 255
cephalothin against, 88
ciprofloxacin against, 79, 88, 143, 188,
346
cotrimoxazole against, 88
desacetylcefotaxime against, 255
desmethylfleroxacin against, 255
desmethylfleroxacin/desacetylcefotaxime
against, 255
enoxacin against, 74, 88
erythromycin against, 88
fleroxacin against, 255
HRE 664 against, 509
lomefloxacin against, 74
optochin-resistant variants of, 63
penicillin against, 88
quinolones against, 195
resistance in, 85
Ro 24-6778 against, 255
sparfloxacin against, 346
tetracycline against, 74
vancomycin against, 346
- Streptococcus pyogenes*
cefotaxime against, 88, 255
cephalothin against, 88
ciprofloxacin against, 88
cotrimoxazole against, 88
desacetylcefotaxime against, 255
desmethylfleroxacin against, 255
desmethylfleroxacin/desacetylcefotaxime
against, 255
enoxacin against, 88
erythromycin against, 88
fleroxacin against, 255
penicillin against, 88
quinolones against, 195
resistance levels of routine isolates of,
89
- Ro 24-6778 against, 255
- Streptococcus zooepidemicus*
cefotaxime against, 88
cephalothin against, 88
ciprofloxacin against, 88
cotrimoxazole against, 88
enoxacin against, 88
erythromycin against, 88
penicillin against, 88
resistance levels of routine isolates of,
89
- Streptomycin
resistance to, 29
- Strongyloides stercoralis*
rapid identification of, 274
- Sulbactam
antimicrobial activity of, 45, 51
- Sulfadiazine
resistance to, 29
- Sulfamethoxazole
antimicrobial activity of, 80
- Sulfamethoxazole/trimethoprim
antimicrobial activity of, 29
- Sulfisoxazole
resistance to, 29
- Sulfociprofloxacin
extravascular penetration of, 110
transintestinal elimination of, 128
- Surgical prophylaxis
ampicillin in, 321
cefamandole in, 321
cefazolin in, 320
cefoxatime in, 317
ceftazidime in, 320
ceftriaxone in, 320
cephradine in, 320
methenamine in, 320
mezlocillin in, 320
piperacillin in, 320
pivampicillin in, 320
pivmecillinan in, 320
ticarcillin/clavulanic acid in, 321
tinidazole in, 321
- Systemic lupus erythematosus
Campylobacter upsaliensis sepsis in, 367
- Temafloxacin
antimicrobial activity of, 334
- Terconazole
effects of on sterol and carbohydrate
composition of *Candida albicans*, 31
- Tetracycline
antimicrobial activity of, 65, 71, 80, 149,
277
resistance to, 29, 85
- Theophylline
metabolism, ciprofloxacin inhibition of,
135

- Throat swabs
 detection of group A streptococcal antigen from, 209
- Ticarcillin
 antimicrobial activity of, 80, 321
 resistance to, 86
- Ticarcillin/clavulanic acid
 antimicrobial activity of, 357
- Time-kill kinetic studies
 cefotetan activity assessed via, 311
 cefoxitin activity assessed via, 311
 ceftiozoxime activity assessed via, 311
 daptomycin activity assessed via, 245
 penicillin G activity assessed via, 311
 vancomycin activity assessed via, 245
- Tinidazole
 antimicrobial activity of, 321
- TNF, *See* Tumor necrosis factor
- TNF- α , *See* Tumor necrosis factor- α
- Tobramycin
 antimicrobial activity of, 80
 resistance to, 85
- Toluidine blue O stain
 Pneumocystis carinii detected via, 307
- Tosufloxacin (A-61827)
 antimicrobial activity of, 333
- Toxoplasma gondii*
 transmission of, 1
- Transintestinal elimination
 of ciprofloxacin, 127
- Triazoles
 broad spectrum, against fungal pathogens, 39
- Trimethoprim
 antimicrobial activity of, 29, 80
- Trimethoprim/sulfamethoxazole
 antifungal activity of, 1
 antimicrobial activity of, 277
- Trypanosoma cruzi*
 infection, colony-stimulating factors against, 387
- Tuberculosis
 pulmonary, diagnosis of, 235
- Tuberculoheptanoic acid
 measurement of, in diagnosis of tuberculosis, 235
- Tumor necrosis factor (TNF)
 against *Candida albicans*, 383
 in malaria, 435
 in parasitic diseases, 387
 in septic shock, 377
- Tumor necrosis factor- α (TNF- α)
 sepsis syndrome, lung injury in, 397
- Tunica mucosa
 ciprofloxacin concentration in, 177
- Ureaplasma urealyticum*
 in wound infections, after Cesarean section, 363
- Urease test
 Helicobacter pylori detected via, 449
- Urinary tract infection
 ceftazidime against, 157, 161
 ciprofloxacin against, 157, 161
 naladixic acid against, 153, 157
- Urine
 ciprofloxacin elimination via, 128
 cytomegalovirus detection in, 42
- Urogenital samples
 Neisseria gonorrhoeae detection in, 217
- Vancomycin
 antimicrobial activity of, 67, 87, 245, 345
 resistance to, 87
- Veillonella* spp.
 cefoxitin against, 59
 chloramphenicol against, 59
 clindamycin against, 59
 imipenem against, 57
- meropenem against, 57
 metronidazole against, 59
 piperacillin against, 58
- Very low birth weight infants
 nasopharyngeal cultures of, coagulase-negative staphylococcal isolates from, 17
- Vibrio cholerae*
 rapid identification of, 275
- Vibrio* spp.
 ciprofloxacin against, 333, 334
 erythromycin against, 334
 lomefloxacin against, 334
 norfloxacin against, 334
 temafloxacin against, 334
 tosufloxacin against, 334
- Vibrio vulnificans*
 environmental strains, enhancement of virulence of, 285
- Wound infection
 after Cesarean section, 363
- Xanthomonas hydrophila*
 Ro 24-6778 against, 253
- Xanthomonas maltophilia*
 ciprofloxacin against, 167, 174, 347
 imipenem against, 347
 quinolones against, 196
 Ro 24-6778 against, 258
 sparfloxacin against, 347
- Yersinia enterocolitica*
 ciprofloxacin against, 334
 erythromycin against, 334
 lomefloxacin against, 334
 norfloxacin against, 334
 Ro 24-6778 against, 258
 temafloxacin against, 334
 tosufloxacin against, 334

